Gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.

被引：0
|
作者：
Yoshioka, Hiroshige
Watanabe, Satoshi
Sakai, Hiroshi
Hotta, Katsuyuki
Takenoyama, Mitsuhiro
Yamada, Kazuhiko
Sugawara, Shunichi
Takiguchi, Yuichi
Hosomi, Yukio
Tomii, Keisuke
Niho, Seiji
Yamamoto, Nobuyuki
Nishio, Makoto
Ohe, Yuichiro
Kamada, Ami
Suzukawa, Kazumi
Omori, Yukie
Enatsu, Sotaro
Nakagawa, Kazuhiko
Tamura, Tomohide
机构：
[1] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan
[3] Saitama Canc Ctr, Thorac Oncol, Saitama, Japan
[4] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[5] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan
[6] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
[7] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
[8] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan
[9] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[10] Kobe City Med Ctr, Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9038
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase lb and randomized, open-label, multicenter, phase 2 trial in Japan
    Watanabe, Satoshi
    Yoshioka, Hiroshige
    Sakai, Hiroshi
    Hotta, Katsuyuki
    Takenoyama, Mitsuhiro
    Yamada, Kazuhiko
    Sugawara, Shunichi
    Takiguchi, Yuichi
    Hosomi, Yukio
    Tomii, Keisuke
    Niho, Seiji
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Kato, Terufumi
    Takahashi, Toshiaki
    Kamada, Ami
    Suzukawa, Kazumi
    Omori, Yukie
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    LUNG CANCER, 2019, 129 : 55 - 62
  • [2] SUBGROUP ANALYSIS OF ELDERLY PATIENTS IN SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF NECITUMUMAB (N) PLUS GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY VERSUS GC ALONE IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC)
    Thatcher, N.
    Ciuleanu, T. -E.
    Ramlau, R.
    Schumann, C.
    Paz-Ares, L.
    Depenbrock, H.
    Nanda, S.
    Chouaki, N.
    Socinski, M.
    ANNALS OF ONCOLOGY, 2015, 26
  • [3] Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
    Paz-Ares, L.
    Socinski, M. A.
    Shahidi, J.
    Hozak, R. R.
    Soldatenkova, V.
    Kurek, R.
    Varella-Garcia, M.
    Thatcher, N.
    Hirsch, F. R.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1573 - 1579
  • [4] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan (vol 129, pg 55, 2019)
    Watanabe, Satoshi
    Yoshioka, Hiroshige
    Sakai, Hiroshi
    Hotta, Katsuyuki
    Takenoyama, Mitsuhiro
    Yamada, Kazuhiko
    Sugawara, Shunichi
    Takiguchi, Yuichi
    Hosomi, Yukio
    Tomii, Keisuke
    Niho, Seiji
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Kato, Terufumi
    Takahashi, Toshiaki
    Kamada, Ami
    Suzukawa, Kazumi
    Omori, Yukie
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    LUNG CANCER, 2019, 132 : 157 - 158
  • [5] A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
    Thatcher, Nick
    Hirsch, Fred R.
    Szczesna, Aleksandra
    Ciuleanu, Tudor-Eliade
    Szafranski, Wojciech
    Dediu, Mircea
    Ramlau, Rodryg
    Galiulin, Rinat
    Balint, Beatrix
    Losonczy, Gyorgy
    Kazarnowicz, Andrzej
    Park, Keunchil
    Schumann, Christian
    Reck, Martin
    Paz-Ares, Luis
    Depenbrock, Henrik
    Nanda, Shivani
    Kruljac-Letunic, Anamarija
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
    Paz-Ares, L.
    Socinski, M. A.
    Shahidi, J.
    Hozak, R. R.
    Soldatenkova, V.
    Thatcher, N.
    Hirsch, F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S153 - S153
  • [7] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    Thatcher, Nick
    Hirsch, Fred R.
    Luft, Alexander V.
    Szczesna, Aleksandro
    Ciuleanu, Tudor E.
    Dediu, Mircea
    Ramlau, Rodryg
    Galiulin, Rinat K.
    Balint, Beatrix
    Losonczy, Gyoergy
    Kazarnowicz, Andrzej
    Park, Keunchil
    Schumann, Christian
    Reck, Martin
    Depenbrock, Henrik
    Nanda, Shivani
    Letunic, Anamarija Kruljac
    Kurek, Raffacl
    Paz-Ares, Luis
    Socinskf, Mark A.
    LANCET ONCOLOGY, 2015, 16 (07): : 763 - 774
  • [8] Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
    Park, Keunchil
    Cho, Eun Kyung
    Bello, Maximino
    Ahn, Myung-Ju
    Thongprasert, Sumitra
    Song, Eun-Kee
    Soldatenkova, Victoria
    Depenbrock, Henrik
    Puri, Tarun
    Orlando, Mauro
    CANCER RESEARCH AND TREATMENT, 2017, 49 (04): : 937 - 946
  • [9] SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS
    Socinski, M. A.
    Paz-Ares, L.
    Luft, A. V.
    Szczesna, A.
    Ciuleanu, T. E.
    Szafranski, W.
    Reck, M.
    Balint, B.
    Park, K.
    Schumann, C.
    Hirsch, F. R.
    Depenbrock, H.
    Nanda, S.
    Chouaki, N.
    Thatcher, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours
    Zilembo, N.
    Giannetta, L.
    Crino, L.
    Bearz, A.
    Amoroso, D.
    Gamucci, T.
    Buscaglia, M.
    Tiseo, M.
    Soldatenkova, V.
    Chouaki, N.
    Depenbrock, H.
    Hirsch, F. R.
    Paz-Ares, L.
    Bidoli, P.
    ANNALS OF ONCOLOGY, 2016, 27
12345